IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment

LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, earlier today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer and the introduction of a 15% stock dividend payment to shareholders.

Read more at globenewswire.com